Table 1.
Characteristics of COVID-19 positive study patients (admission).
| Patients, n | n = 387 |
|---|---|
| Age, years | 66.0 ± 15.81 |
| Males, n | 247/387 (63.8%) |
| Positive medical history: | |
| Arterial hypertension, n | 174/387 (44.9%) |
| Cardiomiopathy, n | 98/387 (25.3%) |
| Chronic kidney insufficiency, n | 40/387 (10.3%) |
| Chronic obstructive pulmonary disease (COPD), n | 38/387 (9.8%) |
| Diabetes mellitus, n | 65/387 (16.8%) |
| Malignancy, n | 53/387 (13.7%) |
| Peripheral arterial disease, n | 50/387 (12.9%) |
| Biochemistry at admission: | |
| Serum creatinine, mg/dL | 1.59 ± 7.34 |
| Azotemia, mg/dL | 51.9 ± 44 |
| PCR, mg/L | 11.85 ± 21.9 |
| IL-6, pg/mL | 91.9 ± 127.9 |
| D-dimer, mcg/mL | 4420.1 ± 22,368 |
| White blood cells, n | 8234.3 ± 4594.8 |
| Lymphocytes, n | 1250.9 ± 2154.9 |
| ALT, IU/L | 67.0 ± 216.7 |
| LDH, IU/L | 342.3 ± 177.3 |
| Ferritin, ng/mL | 876 (26,714; 69) |
| Physical parameters at admission: | |
| Blood pressure, mmHg | 131.1 ± 19.1/75.8 ± 12.0 |
| Heart rate, bpm | 88.4 ± 17.3 |
| Body temperature, degree | 37.9 ± 7.8 |
| PaO2/FiO2 | 267.12 ± 102.5 |
| (Stage 0) PaO2/FiO2 (>300) | 153 (46.7%)/328 |
| (Stage 1) PaO2/FiO2 (300–201) | 89 (27.1%)/328 |
| (Stage 2) PaO2/FiO2 (200–101) | 60 (18.3%)/328 |
| (Stage 3) PaO2/FiO2 (≤100) | 26 (7.9%)/328 |
| Medical therapy at admission: | |
| Angiotensin Converting Enzymes ACEIs, n | 47/386 (12.2%) |
| Angiotensin Receptor Blockers ARBs, n | 39/386 (10.1%) |